Mankind Pharma earnings rose 37.7% in the September 2026 quarter, with profit after tax reaching ₹716 crore as the drugmaker reported strong growth in domestic and international markets.

Mankind Pharma earnings and revenue

Profit after tax increased from ₹520.2 crore in the same quarter a year earlier, the company said in a regulatory filing. Revenue from operations rose to ₹4,337.9 crore from ₹3,697.2 crore.

Vice Chairman and Managing Director Rajeev Juneja attributed the performance to disciplined execution and strengthening business fundamentals.

Entry into CAR-T therapies

Juneja said Mankind’s recent acquisition of Armed Cell Therapeutics marked its entry into next-generation CAR-T therapies. He said the acquisition strengthened the company’s research and development capabilities for future growth.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.